A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma

Michelle MacLean, John G Anderson, Scott J MacGregor, Tracy White, Chintamani D Atreya

Research output: Contribution to journalArticle

Abstract

Bacterial contamination of injectable stored biological fluids such as blood plasma and platelet concentrates preserved in plasma at room temperature is a major health-risk. Current pathogen-reduction technologies (PRT) rely on the use of chemicals and/or ultraviolet-light, which affects product quality and can be associated with adverse events in recipients. 405nm violet-blue light is antibacterial without the use of photosensitizers, and can be applied at levels safe for human exposure, making it of potential interest for decontamination of biological fluids such as plasma. As a pilot study to test whether 405nm light is capable of inactivating bacteria in biological fluids, rabbit and human plasma were seeded with bacteria and treated with a 405nm light emitting diode (LED) exposure system (patent pending). Inactivation was achieved in all tested samples, ranging from low volumes to pre-bagged plasma. 99.9% reduction of low density bacterial populations (≤103 CFUml-1), selected to represent typical ‘natural’ contamination levels, were achieved using doses of 144 Jcm-2. The penetrability of 405nm light, permitting decontamination of pre-bagged plasma, and the non-requirement for photosensitizing agents, provides a new proof-of-concept in bacterial reduction in biological fluids, especially injectable fluids relevant to transfusion medicine.
LanguageEnglish
Article number2920514
Number of pages11
JournalJournal of Blood Transfusion
Volume2016
DOIs
Publication statusPublished - 29 Sep 2016

Fingerprint

Plasmas
Fluids
Decontamination
Bacteria
Contamination
Plasma (human)
Photosensitizers
Health risks
Pathogens
Platelets
Medicine
Light emitting diodes
Blood
Temperature

Keywords

  • bacterial contamination
  • blood plasma
  • pathogen-reduction technologies
  • bacteria inactivation

Cite this

@article{aed79bdac8fb4f69812a981c13a697b2,
title = "A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma",
abstract = "Bacterial contamination of injectable stored biological fluids such as blood plasma and platelet concentrates preserved in plasma at room temperature is a major health-risk. Current pathogen-reduction technologies (PRT) rely on the use of chemicals and/or ultraviolet-light, which affects product quality and can be associated with adverse events in recipients. 405nm violet-blue light is antibacterial without the use of photosensitizers, and can be applied at levels safe for human exposure, making it of potential interest for decontamination of biological fluids such as plasma. As a pilot study to test whether 405nm light is capable of inactivating bacteria in biological fluids, rabbit and human plasma were seeded with bacteria and treated with a 405nm light emitting diode (LED) exposure system (patent pending). Inactivation was achieved in all tested samples, ranging from low volumes to pre-bagged plasma. 99.9{\%} reduction of low density bacterial populations (≤103 CFUml-1), selected to represent typical ‘natural’ contamination levels, were achieved using doses of 144 Jcm-2. The penetrability of 405nm light, permitting decontamination of pre-bagged plasma, and the non-requirement for photosensitizing agents, provides a new proof-of-concept in bacterial reduction in biological fluids, especially injectable fluids relevant to transfusion medicine.",
keywords = "bacterial contamination, blood plasma, pathogen-reduction technologies, bacteria inactivation",
author = "Michelle MacLean and Anderson, {John G} and MacGregor, {Scott J} and Tracy White and Atreya, {Chintamani D}",
year = "2016",
month = "9",
day = "29",
doi = "10.1155/2016/2920514",
language = "English",
volume = "2016",
journal = "Journal of Blood Transfusion",
issn = "2090-9187",

}

TY - JOUR

T1 - A new proof-of-concept in bacterial reduction

T2 - Journal of Blood Transfusion

AU - MacLean, Michelle

AU - Anderson, John G

AU - MacGregor, Scott J

AU - White, Tracy

AU - Atreya, Chintamani D

PY - 2016/9/29

Y1 - 2016/9/29

N2 - Bacterial contamination of injectable stored biological fluids such as blood plasma and platelet concentrates preserved in plasma at room temperature is a major health-risk. Current pathogen-reduction technologies (PRT) rely on the use of chemicals and/or ultraviolet-light, which affects product quality and can be associated with adverse events in recipients. 405nm violet-blue light is antibacterial without the use of photosensitizers, and can be applied at levels safe for human exposure, making it of potential interest for decontamination of biological fluids such as plasma. As a pilot study to test whether 405nm light is capable of inactivating bacteria in biological fluids, rabbit and human plasma were seeded with bacteria and treated with a 405nm light emitting diode (LED) exposure system (patent pending). Inactivation was achieved in all tested samples, ranging from low volumes to pre-bagged plasma. 99.9% reduction of low density bacterial populations (≤103 CFUml-1), selected to represent typical ‘natural’ contamination levels, were achieved using doses of 144 Jcm-2. The penetrability of 405nm light, permitting decontamination of pre-bagged plasma, and the non-requirement for photosensitizing agents, provides a new proof-of-concept in bacterial reduction in biological fluids, especially injectable fluids relevant to transfusion medicine.

AB - Bacterial contamination of injectable stored biological fluids such as blood plasma and platelet concentrates preserved in plasma at room temperature is a major health-risk. Current pathogen-reduction technologies (PRT) rely on the use of chemicals and/or ultraviolet-light, which affects product quality and can be associated with adverse events in recipients. 405nm violet-blue light is antibacterial without the use of photosensitizers, and can be applied at levels safe for human exposure, making it of potential interest for decontamination of biological fluids such as plasma. As a pilot study to test whether 405nm light is capable of inactivating bacteria in biological fluids, rabbit and human plasma were seeded with bacteria and treated with a 405nm light emitting diode (LED) exposure system (patent pending). Inactivation was achieved in all tested samples, ranging from low volumes to pre-bagged plasma. 99.9% reduction of low density bacterial populations (≤103 CFUml-1), selected to represent typical ‘natural’ contamination levels, were achieved using doses of 144 Jcm-2. The penetrability of 405nm light, permitting decontamination of pre-bagged plasma, and the non-requirement for photosensitizing agents, provides a new proof-of-concept in bacterial reduction in biological fluids, especially injectable fluids relevant to transfusion medicine.

KW - bacterial contamination

KW - blood plasma

KW - pathogen-reduction technologies

KW - bacteria inactivation

U2 - 10.1155/2016/2920514

DO - 10.1155/2016/2920514

M3 - Article

VL - 2016

JO - Journal of Blood Transfusion

JF - Journal of Blood Transfusion

SN - 2090-9187

M1 - 2920514

ER -